论文部分内容阅读
结合毒性药材研究现状以及多年来在中成药非处方药遴选与转换的具体实践工作中所积累的经验与认识,思考现阶段可行的含毒性药材中成药评价处理规范。初步建立了非处方药转换中含毒性药材中成药评价思路与方法。基本解决了目前在中成药非处方药转换中面临的毒性药材问题,有效促进了工作的开展,对方便消费者用药、保障其用药安全具有重要意义增强非处方药转换中含毒性药材中成药评价的科学、公正,保证公众自我药疗中的用药安全。
Based on the research status of toxic medicinal materials and the experience and understanding accumulated over the years in the selection and conversion of proprietary Chinese medicines (TCM) over the years, we considered the feasible norms for evaluation and processing of proprietary Chinese medicines containing toxic herbs at this stage. Preliminary establishment of non-prescription drug conversion toxic medicines proprietary Chinese medicines evaluation ideas and methods. It basically solved the problem of toxic medicinal materials currently facing the conversion of proprietary Chinese medicines from non-prescription drugs, effectively promoted the work, and made it convenient for consumers to take medicines and ensure the safety of medicines. It is of great significance to enhance the scientific and fair evaluation of proprietary Chinese medicines in the transformation of non-prescription medicines. , To ensure that the public self-medication medication safety.